Silence in this case is a good thing right? BIOD has quietly built a nice pipeline of diabetes drugs. Being in a market that is growing and where major patent expirations the next few years from existing solutions will occur, I haven't quite understood why a little more focus has not been shown towards the company. If Amylin was worth $3.5B (minus some payments) and MNKD is potentially worth $11B, then BIOD is probably worth somewhere in between if trials continue to go well. ....closer to $3.5B IMHO though. Due the math, and you can see the stock potential.